Lu-177-PSMA is a type of radioactive therapy used in the treatment of prostate cancer. The treatment involves administering Lu-177-labeled psma-617, a synthetic molecule that binds to specific proteins found on the surface of prostate cancer cells. The radiation emitted from the Lu-177 then damages the DNA of these cells, leading to their death. This targeted therapy can help improve patient outcomes and reduce side effects compared to traditional methods like chemotherapy.
Lu-177-PSMA is a type of radioactive therapy used in the treatment of prostate cancer. The treatment involves administering Lu-177-labeled psma-617, a synthetic molecule that binds to specific proteins found on the surface of prostate cancer cells. The radiation emitted from the Lu-177 then damages the DNA of these cells, leading to their death. This targeted therapy can help improve patient outcomes and reduce side effects compared to traditional methods like chemotherapy.